Outlook Therapeutics, Inc. (OTLK) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 50.76
30Y Low18.5·High71.9
ROE
↑
N/A
—
5yr avg: -1210.2%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
OTLK Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Outlook Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $14M | $27M | $99M | $55M | $259M | $331M | $52M | $27M | $56M | $33M | $73M |
| Enterprise Value | $-7835373075148 | $-7835359995440 | $114M | $67M | $252M | $329M | $49M | $34M | $76M | $48M | $80M |
| P/E Ratio → | -0.12 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 9.85 | 19.10 | — | — | — | — | — | 3.33 | 17.98 | 8.64 | 24.55 |
| P/B Ratio | — | — | — | — | 29.62 | 71.91 | 18.49 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
OTLK EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -5543095.85 | — | — | — | — | — | 4.18 | 24.52 | 12.64 | 26.69 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
OTLK Profitability
Margins and return-on-capital ratios measuring operating efficiency
Outlook Therapeutics, Inc. earns an operating margin of -4744.3%.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 46.5% | 46.5% | — | — | — | — | — | -192.2% | — | — | — |
| Operating Margin | -4744.3% | -4744.3% | — | — | — | — | — | -445.6% | -960.0% | -941.2% | -1723.1% |
| Net Profit Margin | -4416.2% | -4416.2% | — | — | — | — | — | -423.8% | -974.5% | -1019.1% | -1788.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -990.0% | -1430.5% | -1247.0% | — | — | — | — |
| ROA | -0.0% | -0.0% | -246.6% | -193.9% | -257.3% | -249.9% | -191.2% | -175.2% | -139.9% | -174.8% | -301.9% |
| ROIC | — | — | — | -342086.3% | -2184.8% | -6926.2% | — | — | — | — | -3267.2% |
| ROCE | — | — | — | — | -507.5% | -519.8% | -10697.2% | — | — | — | -1570.7% |
OTLK Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $8.1T exceeds total debt of $247.7B, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 1.25 | 2.58 | 3.11 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -0.74 | -0.56 | -1.32 | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -236.86 | -236.86 | -22.71 | -34.06 | -42.41 | -55.26 | -20.98 | -10.47 | -7.62 | -6.38 | -27.73 |
Net cash position: cash ($8.08T) exceeds total debt ($247.7B)
OTLK Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.38x is below 1.0, meaning current liabilities exceed current assets — though the company's $8.1T cash position helps mitigate short-term liquidity concerns. The current ratio has declined from 0.66x to 0.38x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.38 | 0.38 | 0.64 | 0.66 | 1.39 | 3.19 | 1.13 | 0.67 | 0.10 | 0.14 | 0.28 |
| Quick Ratio | 0.31 | 0.31 | 0.64 | 0.66 | 1.39 | 3.19 | 1.13 | 0.67 | 0.10 | 0.14 | 0.28 |
| Cash Ratio | 0.18 | 0.18 | 0.35 | 0.50 | 0.88 | 2.14 | 0.79 | 0.40 | 0.05 | 0.11 | 0.12 |
| Asset Turnover | — | 0.00 | — | — | — | — | — | 0.48 | 0.14 | 0.18 | 0.13 |
| Inventory Turnover | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 385.00 | — | — | — | — | — | — | — | — | — |
OTLK Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Outlook Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 100.0% | 100.0% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | 0.0% |
| Shares Outstanding | — | $25M | $19M | $13M | $11M | $8M | $4M | $909591 | $354026 | $150261 | $107581 |
Peer Comparison
Compare OTLK with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 OTLKYou | $14M | -0.1 | — | — | 46.5% | -4744.3% | — | — | — |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 ADVM | $96M | -0.7 | — | — | 100.0% | -13915.9% | -189.8% | -124.2% | — |
 REPL | $266M | -1.1 | — | — | — | — | -62.6% | -51.9% | — |
 NUVL | $8B | -17.5 | — | — | — | — | -36.7% | -32.5% | — |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 GMAB | $17B | 17.6 | 15.4 | 14.5 | 91.7% | 33.6% | 4.5% | 5.0% | 4.1 |
 OCUL | $2B | -6.8 | — | — | 87.3% | -521.0% | -54.9% | — | — |
 SGHT | $286M | -7.1 | — | — | 86.2% | -48.0% | -50.7% | -274.4% | — |
 AVXL | $289M | -5.8 | — | — | — | — | -43.1% | — | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
See OTLK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OTLK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OTLK vs RCKT
Side-by-side business, growth, and profitability comparison vs Rocket Pharmaceuticals, Inc..
Start ComparisonOTLK — Frequently Asked Questions
Quick answers to the most common questions about buying OTLK stock.
What is Outlook Therapeutics, Inc.'s P/E ratio?
Outlook Therapeutics, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Is OTLK stock overvalued?
Based on historical data, Outlook Therapeutics, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Outlook Therapeutics, Inc.'s profit margins?
Outlook Therapeutics, Inc. has 46.5% gross margin and -4744.3% operating margin.